Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.
Explore this paper's citation graph
Summary
CYP3A genetic factors were varied in different stages after transplantation and the role of CYP3A7 in cyclosporine metabolism requires further study.
- Type
- article
- Published
- 2017-09-27
- Cited by
- 23
- References
- 41
- OpenAlex
- https://openalex.org/W2758238650
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12520464
Keywords
Renal transplant, CYP3A, Medicine, Pharmacology, Pharmacogenetics
References
- Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.
- CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.
- Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2
- No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
- Evaluation of 6β-Hydroxycortisol and 6β-Hydroxycortisone as Biomarkers for Cytochrome P450 3A Activity: Insight into Their Predictive Value for Estimating Oral Immunosuppressant Metabolism.
- Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy.
- Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers
- Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population
- CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
- The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity
- The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
- Screening for SNPs and haplotypes in the CYP3A7 gene in Chinese populations.
- Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
- Genetic contribution to variable human CYP3A-mediated metabolism.
- Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China
- CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients
- Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
- An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
- CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele
Cited by
- Sexual Dimorphism in Drug Metabolism and Pharmacokinetics.
- The Pharmacogenetics of Immune-Modulating Therapy.
- Metabolic Pathway of Cyclosporine A and Its Correlation with Nephrotoxicity.
- Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping
- CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria
- Caveolin-1 rs4730751 single-nucleotide polymorphism may not influence kidney transplant allograft survival
- Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers
- Significance of ethnic factors in immunosuppressive therapy management after organ transplantation.
- Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
- Pharmacogenetic and safety analysis of cinacalcet hydrochloride in healthy Chinese subjects
- Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin A in allogeneic haematopoietic stem cell transplantation recipients
- CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
- Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
- PharmVar GeneFocus: CYP3A5
- Impact of CYP3A7, CYP2D6 and ABCC2/ABCC3 polymorphisms on tacrolimus steady state concentrations in Bulgarian kidney transplant recipients
- Role of cyclosporin A in the treatment of kidney disease and nephrotoxicity.
- Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical Overview
- Correlation of renal function with intra-patient variability of tacrolimus concentration among recipients of renal transplants: a 10-year study
- Cyclosporine Transporter Pharmacogenomic Effect in Transplantation: An Updated Systematic Review
- The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients
Related papers
- Modulation of Hepatic Cytochrome P450 Enzymes by Curcumin and its Pharmacokinetic Consequences in Sprague–dawley Rats
- Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity
- Modulation of Cytochrome P450 Activity by 18β‐Glycyrrhetic Acid and its Consequence on Buspirone Pharmacokinetics in Rats
- In vivo effect of Schisandrin B on cytochrome P450 enzyme activity.
- Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers
- Effect of danshen extract on the activity of CYP3A4 in healthy volunteers.
- Inhibitory effect of 20(S)-protopanaxadiol on cytochrome P450: Potential of its pharmacokinetic interactions in vivo.
- Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.
- Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects
- Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure